Contineum Therapeutics, Inc. CTNM
Set alert
9.56 USD +0.17 +1.81%
At close
9.45 -0.11 -1.15%
Pre-market · Nov 3, 5:44 AM ET
9.13 Day range 9.64
6.73 52-week range 17.79
- YTD
- -16.36%
- 1 year
- -13.17%
- Open
- 9.46
- Prev close
- 9.39
- Mkt cap
- 359.66M
- Vol
- 369.01K
- Avg vol
- 835.20K
- EPS
- -1.73
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 9.13
- High
- 9.64
- Forward P/E
- -7.68
- Beta
- 0.00
- Short ratio
- 13.66
- Inst. own
- 72.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 5, 2025
- 50-d avg
- 15.77
- 200-d avg
- 17.15
- 1y target
- 29.25
6M chart
Signals (28)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 27, 2026 | 6 days ago |
| MACD: Sell Signal | Oct 12, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 12, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 6, 2026 | 3 weeks ago |
| RSI: Oversold | Sep 29, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| MACD: Buy Signal | Aug 20, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 30, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 15, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| SMA: Bullish | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 17, 2026 | 4 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
Newest 20 of 28.
Analyst view
Consensus: none
Price target (mean) 29.25 +206.0% upside
Now 9.56
- Target (low)
- 25.00
- Target (mean)
- 29.25
- Target (high)
- 32.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.435 | -0.50 – -0.37 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next quarter | 0.00 | 0.00 – 0.00 | -3.55 | 0.0% | 0 | 0.0% | 0 |
| Current year | -1.90 | -2.11 – -1.51 | 0.00 | 0.0% | 0 | 0.0% | 4 |
| Next year | -1.62 | -2.03 – -0.71 | -1.90 | +14.9% | 10.00M | 0.0% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 22, 2024 | Baird | Initiated | — | Outperform |
| Aug 14, 2024 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 30, 2024 | RBC Capital | Initiated | — | Outperform |
| Apr 30, 2024 | Stifel | Initiated | — | Buy |
| Apr 30, 2024 | Morgan Stanley | Initiated | — | Overweight |